Literature DB >> 25043982

Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival.

Cielito C Reyes-Gibby1, Karen O Anderson2, Kelly W Merriman3, Knox H Todd3, Sanjay S Shete4, Ehab Y Hanna5.   

Abstract

UNLABELLED: Survival outcomes in patients with squamous cell carcinoma of the head and neck (HNSCC) vary by extent of disease, behavioral factors, and socioeconomic factors. We assessed the extent to which pretreatment pain influences survival in 2,340 newly diagnosed patients with HNSCC, adjusting for disease stage, symptoms, pain medications, comorbidities, smoking, alcohol consumption, age, sex, and race/ethnicity. Patients rated their pain at presentation to the cancer center (0 = "no pain" and 10 = "pain as bad as you can imagine"). Survival time was calculated from the date of diagnosis to the date of death of any cause or last follow-up. Five-year overall survival was calculated for all the variables assessed in the study. Severe pain (≥7) was most prevalent among those with oral cancer (20.4%; pharynx = 18.8%; larynx = 16.1%) and significantly varied by tumor stage, fatigue severity, smoking status, comorbid lung disease, and race (all P < .05) across cancer diagnoses. Overall 5-year survival varied by pain for oral (severe pain = 31% vs nonsevere pain = 52%; P < .001) and pharyngeal cancer (severe pain = 33% vs nonsevere pain = 53%; P < .001). Multivariable analyses showed that pain persisted as an independent prognostic factor for survival. Pain reported prior to treatment should be considered in understanding survival outcomes in HNSCC patients. PERSPECTIVE: Pretreatment pain was an independent predictor of survival in a large sample of HNSCC patients even after accounting for tumor node metastasis stage, fatigue, age, race/ethnicity, smoking, and alcohol intake. Therefore, symptoms at presentation and before cancer treatment are important factors to be considered in understanding survival outcomes in HNSCC patients.
Copyright © 2014 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pain; depression; fatigue; head and neck; survival; symptoms

Mesh:

Year:  2014        PMID: 25043982      PMCID: PMC4418559          DOI: 10.1016/j.jpain.2014.07.003

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  36 in total

1.  Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients.

Authors:  Mogens Groenvold; Morten Aagaard Petersen; Ellen Idler; Jakob Bue Bjorner; Peter M Fayers; Henning T Mouridsen
Journal:  Breast Cancer Res Treat       Date:  2007-01-03       Impact factor: 4.872

Review 2.  Molecular epidemiology, cancer-related symptoms, and cytokines pathway.

Authors:  Cielito C Reyes-Gibby; Xifeng Wu; Margaret Spitz; Razelle Kurzrock; Michael Fisch; Eduardo Bruera; Sanjay Shete
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

Review 3.  Racial and ethnic disparities in pain: causes and consequences of unequal care.

Authors:  Karen O Anderson; Carmen R Green; Richard Payne
Journal:  J Pain       Date:  2009-12       Impact factor: 5.820

4.  Long-term quality of life after total laryngectomy.

Authors:  Isabel Vilaseca; Amy Y Chen; Andrea G Backscheider
Journal:  Head Neck       Date:  2006-04       Impact factor: 3.147

Review 5.  Sex differences in pain perception.

Authors:  Zsuzsanna Wiesenfeld-Hallin
Journal:  Gend Med       Date:  2005-09

6.  The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care.

Authors:  Cielito C Reyes-Gibby; Badi El Osta; Margaret R Spitz; Henrique Parsons; Razelle Kurzrock; Xifeng Wu; Sanjay Shete; Eduardo Bruera
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 7.  Cancer and orofacial pain.

Authors:  Dena J Fischer; Gary D Klasser; Joel B Epstein
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2008-05       Impact factor: 2.802

8.  Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.

Authors:  Cielito C Reyes-Gibby; Sanjay Shete; Sriram Yennurajalingam; Marsha Frazier; Eduardo Bruera; Razelle Kurzrock; Christopher H Crane; James Abbruzzese; Douglas Evans; Margaret R Spitz
Journal:  J Pain Symptom Manage       Date:  2009-12       Impact factor: 3.612

9.  Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality.

Authors:  Brant A Inman; Viet-Tan Tran; Yves Fradet; Louis Lacombe
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

10.  The role of pain in head and neck cancer recurrence and survivorship.

Authors:  Joseph Scharpf; Lucy Hynds Karnell; Alan J Christensen; Gerry F Funk
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-08
View more
  32 in total

1.  Symptoms at diagnosis as independent prognostic factors in retroperitoneal liposarcoma.

Authors:  Satoru Taguchi; Haruki Kume; Hiroshi Fukuhara; Teppei Morikawa; Shigenori Kakutani; Yuta Takeshima; Hideyo Miyazaki; Motofumi Suzuki; Tetsuya Fujimura; Tohru Nakagawa; Akira Ishikawa; Yasuhiko Igawa; Yukio Homma
Journal:  Mol Clin Oncol       Date:  2015-12-08

2.  Pathogenesis and prognosis of primary oral squamous cell carcinoma based on microRNAs target genes: a systems biology approach.

Authors:  Amir Taherkhani; Shahab Shahmoradi Dehto; Shokoofeh Jamshidi; Setareh Shojaei
Journal:  Genomics Inform       Date:  2022-09-30

3.  Sympathetic modulation of tumor necrosis factor alpha-induced nociception in the presence of oral squamous cell carcinoma.

Authors:  Megan Atherton; Stella Park; Nicole L Horan; Samuel Nicholson; John C Dolan; Brian L Schmidt; Nicole N Scheff
Journal:  Pain       Date:  2022-04-20       Impact factor: 7.926

4.  Association of Symptoms and Clinical Findings With Anticipated Outcomes in Patients With Recurrent Head and Neck Cancer.

Authors:  Patrik Pipkorn; Jordan Licata; Dorina Kallogjeri; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-08-01       Impact factor: 6.223

5.  The Histopathology of Oral Cancer Pain in a Mouse Model and a Human Cohort.

Authors:  K Naik; M N Janal; J Chen; D Bandary; B Brar; S Zhang; J C Dolan; B L Schmidt; D G Albertson; A Bhattacharya
Journal:  J Dent Res       Date:  2020-10-08       Impact factor: 6.116

6.  Cohort study of oncologic emergencies in patients with head and neck cancer.

Authors:  Cielito C Reyes-Gibby; Stephanie C Melkonian; Ehab Y Hanna; Sai-Ching J Yeung; Charles Lu; Mark S Chambers; Srinivas R Banala; Gary B Gunn; Sanjay S Shete
Journal:  Head Neck       Date:  2017-03-27       Impact factor: 3.821

7.  A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer.

Authors:  Gregory M Hermann; Austin J Iovoli; Alexis J Platek; Chong Wang; Austin Miller; Kristopher Attwood; Daniel J Bourgeois; Anurag K Singh
Journal:  Cancer       Date:  2019-12-23       Impact factor: 6.921

8.  Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation.

Authors:  Nicole N Scheff; Yi Ye; Aditi Bhattacharya; Justin MacRae; Dustin N Hickman; Atul K Sharma; John C Dolan; Brian L Schmidt
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

9.  Flourishing in head and neck cancer survivors.

Authors:  Alexandria Harris; Jinhong Li; Karley Atchison; Christine Harrison; Daniel Hall; Tyler VanderWeele; Jonas T Johnson; Marci L Nilsen
Journal:  Cancer Med       Date:  2022-03-11       Impact factor: 4.711

10.  Seeding of breast cancer cell line (MDA-MB-231LUC+) to the mandible induces overexpression of substance P and CGRP throughout the trigeminal ganglion and widespread peripheral sensory neuropathy throughout all three of its divisions.

Authors:  Silvia Gutierrez; James C Eisenach; M Danilo Boada
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.